We have evaluated objectively pain tolerance in transrectal ultrasound-guided prostate biopsy (TRUS) using local periprostatic per rectal anesthesia as compared to the conventional method. From November 2008 to May 2009, 90 patients underwent transrectal ultrasound-guided prostate biopsy at Department of Urology, Clinical Center University Sarajevo. 90 patients who fulfilled the inclusion criteria were randomized into 3 groups of 30 patients each. Group 1 received periprostatic local anesthesia with 2% lidocaine, group 2 received Voltaren supp placed in rectum an hour before biopsy while group 3 received no local anesthesia. Pain scale responses were analyzed for each aspect of the biopsy procedure with a visual analog scale of 0-none to 10-maximal. There was no difference between the 3 groups in pain scores during digital rectal examination, intrarectal injection and probe insertion. The mean pain scores during needle insertion in group 1 receiving periprostatic nerve block and in group 2 receiving Voltaren supp were 3,10 +/- 2,32 and 5,15 +/- 2,01 respectively. In group 3 (no local anesthesia), mean pain scores were 6,06 +/- 2,95 which was found to be significantly different (p < 0,001). However, morbidity after the biopsy was not statistically different between all 3 groups. TRUS-guided prostate biopsy is a traumatic and painful experience, but the periprostatic blockage use is clearly associated with more tolerance and patient comfort during the exam. It is an easy, safe, acceptable and reproducible technique and should be considered for all patients undergoing TRUS biopsy regardless of age or number of biopsies.

OBJECTIVE It is known that ESWL can promote acute renal injuries and long-term complications of renal vasculature. Effects on renal vasculature can be evaluated by color Doppler ultrasonography measuring renal resistive index (RI). This prospective study aimed to determine the influence of number of delivered SW-s, used kV and changes in renal resistive index. PATIENTS AND METHODS Total of 60 normotensive patients, 38 males (63%) and 22 females (37%), with renal stones 6-18 mm in size were included in this study. Median age was 42.3 years (range 22-55). RI was measured at interlobar artery before, 1, 3, 5 and 30 days after treatment on treated and contra lateral non-treated kidney. Patients were divided in two groups: Group I (N=25) received 2000 SWs; 0-2 units; (0.5 unit each 500 SWs) Group II (N=35) received 4000 SWs, 0-4 units; (0.5 unit each 500 SWs). RESULTS In treated kidneys RI significantly increased first and second day after treatment from 0.62 +/- 0.05 at baseline to 0.67 +/- 0.05, p < 0.001 at first and 0.66 +/- 0.05, p < 0.007 on the second day after treatment. Increase of RI seven days after treatment is not significant (0.62 +/- 0.05). The contra lateral, non-treated kidney showed significant changes in RI only first day after treatment (0.64 +/- 0.05), p < 0.01. One month after the treatment RI is on normal values in both kidneys. CONCLUSIONS Resistive index-RI is important parameter in evaluation of renal vasculature. Patients treated by ESWL showed a temporary increase in RI two days after the treatment and only first day in contra lateral non-treated kidney--probably caused by release of substance with vasoconstriction properties (need further investigations).

The objective of this work is to verify the incidence of incidental prostate adenocarcinoma in patients who underwent radical cystoprostatectomy for invasive bladder carcinoma. We have retrospectively reviewed patients who underwent radical cystoprostatectomy for infiltrative bladder tumors in period between 2003 and 2007 year, 94 men with bladder cancer underwent radical cystoprostatectomy at Urology Clinic-University of Sarajevo Clinics Centre. Mean age of patients was 67 years, with age limits ranging between 48 and 79 years. Pathohistological evaluation was used for all specimens from RCP. We found that 9,57% of cystoprostatectomy specimens in patients with bladder cancer also contained incidental prostate cancer. This result was much lower than overall mean frequency of incidentally detected prostate cancer in other series of cystoprostatectomy cases (range, 23%-68%). In conclusion we recommended digital rectal examination (DRE) and prostate-specific antigen (PSA) test as part of the bladder cancer work up and complete removal of the prostate at cystoprostatectomy to prevent residual prostate cancer.